Trial · NCT00106938
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Composite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days. | CAS Group | 3.8 | percentage of participants | ||
| Composite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days. | CEA Group | 3.4 | percentage of participants | ||
| Acute Device Success: Xact Carotid Stent | CAS Group | 96.9 | 95% Confidence Interval 95.6 to 97.8 | percentage of devices | |
| Acute Device Success: Embolic Protection Device System | CAS Group | 97.8 | 95% Confidence Interval 96.7 to 98.6 | Percentage of devices | |
| Procedural Success | CAS Group | 95.6 | percentage of participants | ||
| Composite Morbidity Measure | CAS Group | Composite morbidity measure | 31 | participants | |
| Composite Morbidity Measure | CEA Group | Composite morbidity measure | 17 | participants | |
| Composite Morbidity Measure | CAS Group | Cranial nerve injury | 1 | participants | |
| Composite Morbidity Measure | CEA Group | Cranial nerve injury | 4 | participants | |
| Composite Morbidity Measure | CAS Group | Peripheral nerve injury | 0.0 | participants | |
| Composite Morbidity Measure | CEA Group | Peripheral nerve injury | 0.0 | participants | |
| Composite Morbidity Measure | CAS Group | Vascular injury | 8 | participants | |
| Composite Morbidity Measure | CEA Group | Vascular injury | 3 | participants | |
| Composite Morbidity Measure | CAS Group | Non-cerebral bleeding | 21 | participants | |
| Composite Morbidity Measure | CEA Group | Non-cerebral bleeding | 6 | participants | |
| Composite Morbidity Measure | CAS Group | CEA wound or access artery wound | 3 | participants | |
| Composite Morbidity Measure | CEA Group | CEA wound or access artery wound | 4 | participants | |
| Composite Morbidity Measure | CAS Group | Other complications | 0 | participants | |
| Composite Morbidity Measure | CEA Group | Other complications | 0 | participants | |
| Freedom From Clinically Indicated Target Lesion Revascularization(CI-TLR) | CAS Group | 99.8 | percentage of partcipants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00106938/results